FDA
-
-
-
-
-
-
-
Cumberland Pharmaceuticals Receives FDA Fast Track Designation for its Ifetroban Duchenne Muscular Dystrophy Program
-
-
-
-
-
-
-
RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal
-
-
-
-
-
-
-
Cumberland Pharmaceuticals Reports 23% Revenue Growth Year-to-Date
-
-
-
-
-
-
-
NEW STUDY FINDS CALDOLOR® SAFE AND EFFECTIVE FOR OPIOID-SPARING PAIN MANAGEMENT IN OLDER ADULTS
-
-
-
-
-
-
-
VIBATIV® RECEIVES MARKETING APPROVAL IN CHINA
-
-
-
-
-
-
-
CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
-
-
-
-
-
-
-
NEW REPORT SUPPORTS USE OF CALDOLOR® AS A STANDARD OF CARE ACROSS PATIENT POPULATIONS
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

